Professor John Rinn has joined the faculty of the University of Colorado in Boulder, to better understand how RNA genes can interact and influence protein gene function. This goal requires high-throughput screening of RNA molecules for those with specific biological activity and creative computational solutions towards understanding the molecular grammar underlying how RNA “speaks” to the cell. Specifically, this requires new training platforms and courses in what is now termed Bioinformatics that seamless blends experimental and computational logic.
Bioinformatics is a new field that blends elements of biology, statistics, computer science, and genetic engineering. It developed as a solution to a major problem: the sheer abundance of data that cannot be analyzed with mechanical devices. Bioinformatics detects data patterns that shed new light on biological processes. With new an emerging applications of machine learning computational methods for deeper insights into big data.
The discipline has streamlined the invention of new treatments for cancer and determined genetic causes for many diseases. Its techniques are well-suited to precision medicine – the customization of medicine to individual circumstances. It also plays a key role in diagnosing and preventing illnesses such as the flu, heart disease, and diabetes.
This growing field has many applications for pharmaceutical companies, software developers and biotechnology. Further evidence of its influence is the fact that more than 45 American colleges and universities now offer degrees in bioinformatics.
Now teaching at the University of Colorado in Boulder, John Rinn focuses on research into the influence of ribonucleic acid (RNA) on establishing unique cellular states in development and disease. His research focus on the noncoding positions of the human genome, the regions that don’t encode for classic protein coding genes. This requires modifying the human genome in stem cell lines to uncover novel regulatory elements that are required to maintain the pluripotent state or prevent cellular differentiation. This also requires genome modifications that represent those identified in human disease, the vast majority of which reside in the noncoding genome.
The advent of CRISPR technologies turbo-boosted these efforts in several ways. Primarily, with the new throughput and ease of screening thousands of previous unexplored regions of the human genome for biological activity. Also this facilitated developing new tools such as CRISPR-Display that serves as a cellular drone. Where the location and cargo can be specified by specific RNA molecule extensions to CRISPR-CAS9 guide sequences (https://en.wikipedia.org/wiki/CRISPR-Display).
Although CRISPR first caught the public eye in 2018, when a Korean scientist allegedly created HIV-resistant babies, scientists have known about it for nine years. CRISPRs are sequences of genetic material that were first found in bacteria and other microorganisms. They allow these invisible creatures to defend themselves by breaking up pieces of harmful DNA.
Later research has shown that CRISPR’s are found in many forms of life. These versatile molecules can be used to make alterations in DNA much faster and cheaper than previous methods.
These so-called biological machines have several applications. They have been used to vaccinate yogurt against viruses and create crops that can better withstand droughts. It’s thought that one day, CRISPRs could destroy entire populations of mosquitos or bring extinct species back to life.
However, their use raises serious ethical questions about placing them in the human body. The method is imprecise – it could inadvertently damage beneficial DNA. Where do we draw the line between using CRISPRs to cure diseases and enhancing desirable traits? Is it right to make changes without the consent of humans yet to be born?
In response, the National Academies of Sciences, Engineering and Medicine has recommended that CRISPRs be restricted to treating serious diseases that have no other cure. Risks and benefits should be fully publicized and monitored during clinical trials. Finally, research into human side effects should span several generations.
Former Harvard University professor John Rinn is a Leslie Orgel professor of RNA science at the University of Colorado (UC), Boulder. More specifically, John Rinn is a faculty member of the Interdisciplinary Quantitative (IQ) Biology PhD program offered through the institution’s BioFrontiers Institute.
The IQ Biology PhD Certificate at UC Boulder is designed to teach engineering, life sciences, applied mathematics, and computer science students the interdisciplinary quantitative skills they need to enable effective collaboration in academia and industry. Students also gain the competencies necessary for well-rounded research and gain in-depth knowledge of fields outside their core competencies.
During their coursework, students participate in several diverse learning programs. For example, they rotate through three different labs where they learn two or more disciplines in their first year. They also complete coursework to address any knowledge gaps in interdisciplinary topics like quantitative optical imaging. Finally, they attend idea exchanges and work on team projects, as well as boot camps offering short interdisciplinary courses on a variety of topics.
Focused on professional development, IQ Biology also offers internship opportunities in top biotechnology companies, national labs, and, business organizations while promoting participation in outreach activities.
As a doctoral student at Yale University, John Rinn began groundbreaking research in the field of genetics. Following the discovery of a type of RNA known as LINC (large intervening non-coding RNA), John Rinn continued his research as a professor at Harvard University until 2017, when he accepted the Marvin H. Caruthers Endowed Chair for Early-Career Faculty at the BioFrontiers Institute at the University of Colorado Boulder, where he also serves as the Leslie Orgel Professor of RNA Science.
Headed by Nobel Prize recipient Thomas Cech, the BioFrontiers Institute operates under the umbrella of the University of Colorado Boulder. It focuses particularly on cutting-edge research efforts, drawing innovative minds from around the world.
In order to create an environment for its pioneering research, the BioFrontiers Institute encompasses experienced faculty members from a diverse range of academic backgrounds. By bringing together researchers in physical and life sciences as well as professionals in engineering and computer science, the institute encourages exciting collaboration in areas such as genome exploration.
For more information about the BioFrontiers Institute and its current research efforts, visit http://www.colorado.edu/biofrontiers.